PMC6726919_01
Axial image of CT scan before Y90 therapy: an HCC lesion 15 cm in size.
gr1.jpg
PMC6726919_01_gr1.jpg
fig0005
The patient was classified as having Barcelona Clinic Liver Cancer (BCLC) stage B disease, and a Child-Pugh score of A (Fig. 1).
Axial images of CT scan after Y90 therapy: the HCC lesion reduced to 6.5 cm in size.
gr2.jpg
PMC6726919_01_gr2.jpg
fig0010
On follow-up CT scan of the liver 3 months after Y90 therapy, the tumor was reduced to 6.5 cm (Fig. 2).
a,b: Liver volume was analyzed by the Syngo.Via (VB20A_HG05), Siemens Healthineers after Y90 therapy.
gr3.jpg
PMC6726919_01_gr3.jpg
fig0015
According to the follow-up CT scan, the volume of the lateral segment (S2 + S3) and the total liver volume were analyzed by Syngo.Via (Siemens Healthineers; Erlangen, Germany) at 621 mL and 1324 mL, respectively (Fig. 3a,b).
a) Planar view of abdomen in Tc-99 m colloid scintigraphy. Most of the colloid localized in the liver and spleen; only minimal uptake was found on the right lobe and a small amount on bone marrow. b) Fusion image of SPECT-CT in Tc-99 m sulfur colloid scintigraphy. The hypertrophic left lobe took up most of Tc-99 m SC injected; only minimal uptake was found on the right lobe.
gr4.jpg
PMC6726919_01_gr4.jpg
fig0020
Conversely, the left lobe experienced liver hypertrophy (Fig. 4a,b).